Biolexis Therapeutics, Inc. is building BLX-7006, an oral, small-molecule GLP-1 receptor agonist that does not require a cold chain, no injection supply chain, and no fasting requirement.
Public source
Publisher name
Public post
There are more than a billion people who need a GLP-1. Right now most of them will never get one. Injectable GLP-1s ship cold and store cold. Most are dosed weekly, some…
Company
Biolexis Therapeutics, Inc.
Accelerating Drug Discovery
- Industry
- Biotechnology Research
- Location
- Lehi, US
- Company size
- 11–50 employees
About Biolexis Therapeutics, Inc.
Next-generation metabolic medicine, one pill at at time. Biolexis is developing best-in-class oral GLP-1 receptor agonists and complementary AMPK activators designed to deliver injectable-level efficacy with superior tolerability--engineered from day one for convenient daily dosing and fixed-dose combinations.
See moreLatest activity
Latest activity from Biolexis Therapeutics, Inc.
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Products & Services
Moonwalk Biosciences
Moonwalk Biosciences advanced its adipose-targeted RNAi medicines for obesity and cardiometabolic diseases and its lead program MW101 toward the clinic.
Products & Services
Renasant Bio
Renasant Bio is developing oral medicines to address the underlying biology of autosomal dominant polycystic kidney disease (ADPKD) to bring new medicines to all patients with ADPKD.
Products & Services
Revadix
Revadix is translating its scientific foundation into two complementary therapeutic programs: AM-001, a first-generation EPAC1 inhibitor for acute indications, and a new generation of orally available small molecules for broader cardiac and fibrotic indications.
Products & Services
Remepy
Remepy is building an investigational Hybrid Drug for Parkinson's that combines a drug molecule with an adaptive digital protocol into a single prescription.
Research & Knowledge
Structure Therapeutics